Shares of DBV Technologies were trading higher on the Nasdaq after hours Wednesday, following the company confirming alignment with the Food and Drug Administration on an accelerated approval for its ...
Cellectar Biosciences is laying off 60% of its employees and halting work on its sole clinical-stage radiotherapy after the ...
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...
The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...
Qure N.V. QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval ...
Cellectar Biosciences shares fell sharply after it revised its plans for its cancer-focused phospholipid ether drug conjugate platform and said it would cut 60% of its workforce. The stock was ...
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.THIS PRESS RELEASE IS AN ADVERTISEMENT AND ...
"This is a very accelerated timeline," said one alderman. "Moving legislation so fast like this, we just want to make sure we're doing the right thing." ...